Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Juan I, Arenas"'
Autor:
Ioana Riaño, Leticia Martín, Maria Varela, Trinidad Serrano, Oscar Núñez, Beatriz Mínguez, Pedro M. Rodrigues, Maria J. Perugorria, Jesus M. Banales, Juan I. Arenas
Publikováno v:
Cancers, Vol 12, Iss 7, p 1900 (2020)
Pravastatin has demonstrated anti-tumor activity in preclinical and clinical studies. This multicentric randomized double-blind placebo-controlled phase II study (NCT01418729) investigated the efficacy and safety of sorafenib + pravastatin combinatio
Externí odkaz:
https://doaj.org/article/ad8bc37e7f684be5b52e508c735fc1dd
Autor:
Elena, Gomez, Luisa, Garcia Buey, Esther, Molina, Marta, Casado, Isabel, Conde, Marina, Berenguer, Francisco, Jorquera, Miguel-Angel, Simón, Antonio, Olveira, Manuel, Hernández-Guerra, Monica, Mesquita, Jose, Presa, Pedro, Costa-Moreira, Guilherme, Macedo, Juan I, Arenas, Jose, Manuel Sousa, Javier, Ampuero, Rosa M, Morillas, Arsenio, Santos, Armando, De Carvalho, Javier, Uriz, Jose A, Carrión, Maria, Luisa Gutiérrez, Elia, Pérez-Fernández, Conrado M, Fernández-Rodríguez
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 53(4)
Obeticholic acid (OCA) was recently approved as the only on-label alternative for patients with primary biliary cholangitis (PBC) with intolerance or suboptimal response to ursodeoxycholic acid (UDCA). However, few data are available outside clinical
Publikováno v:
Mediators of Inflammation, Vol 2010 (2010)
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming a world-wide public health problem. NAFLD represents a spectrum of disease ranging from “simple steatosis”, which is considered relatively benign, to nonalcoholic steatohepatitis and to
Externí odkaz:
https://doaj.org/article/59bc4e678678438eb14bee97c25ef0c4
Autor:
Jose L, Calleja, Juan M, Pascasio, Belén, Ruiz-Antorán, Francisco, Gea, Rafael, Bárcena, Juan R, Larrubia, Ramón, Pérez-Álvarez, Jose M, Sousa, Manuel, Romero-Gómez, Ricard, Solá, Juan, de la Revilla, Javier, Crespo, Jose M, Navarro, Juan I, Arenas, Manuel, Delgado, Conrado M, Fernández-Rodríguez, Ramon, Planas, Maria, Buti, Xavier, Forns, Vergara
Publikováno v:
Liver International. 35:90-100
Background & Aims The addition of protease inhibitors (PIs) changed the hepatitis C virus (HCV) treatment standards and improved sustained viral response (SVR) rates in patients with genotype 1 HCV infection. Methods Prospective, multicentre, nationa
Autor:
Maria, Buti, Rosa M, Morillas, Juan, Pérez, Martín, Prieto, Ricard, Solà, Antonio, Palau, Moisés, Diago, Lucía, Bonet, Adolfo, Gallego, Javier, García-Samaniego, Milagros, Testillano, Manuel, Rodríguez, Gregorio, Castellano, María L, Gutiérrez, Manuel, Delgado, Antoni, Mas, Manuel, Romero-Gómez, José L, Calleja, Agustina, González-Guirado, Juan I, Arenas, Luisa, García-Buey, Raúl, Andrade, Ana, Gila, Carmen, Vinaixa
Publikováno v:
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Objectives The aim of this study was to evaluate the efficacy and safety of entecavir monotherapy in nucleos(t) ide-naive chronic hepatitis B patients and to analyse the influence of the comorbidity burden on therapy outcome. Methods We retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f33e5c4d3803e51f12f6734647adfc47
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14660
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14660
Autor:
Juan F. Gallegos-Orozco, Jorge Rakela, Marek Nowicki, Tomasz Laskus, Juan I. Arenas, Marek Radkowski, Jonathan Nasseri, Karen V. Kibler, Jeffrey Wilkinson, Hugo E. Vargas
Publikováno v:
Journal of Viral Hepatitis. 13:489-498
Summary. Background: Hepatitis C virus (HCV) translation is initiated in a cap-independent manner by an internal ribosome entry site (IRES) located within the 5′ untranslated region (5′UTR). Sequence changes in this region could affect translatio
Autor:
Hugo E. Vargas, Juan I. Arenas
Publikováno v:
Gastroenterology Clinics of North America. 33:549-562
Chronic hepatitis C virus (HCV) infection is generally a slowly progressive disease. A minority of infected patients, however, eventually will develop cirrhosis and its life-threatening complications.Recent development of combination interferon (IFN)
Publikováno v:
Clinics in Liver Disease. 7:573-584
The present organ donor crisis has led to accepted use of organs from donors infected with hepatitis C virus (HCV) and hepatitis B virus (HBV). Although capable of transmitting disease, these grafts offer opportunities to expand the donor pool for ce
Autor:
Nerea, Muro, Luis, Bujanda, Cristina, Sarasqueta, Inés, Gil, Elizabeth, Hijona, Angel, Cosme, Juan, Arenas, María E, Elosegui, Miren, Sarasola, José, Calpasoro, Juan I, Arenas
Publikováno v:
Gastroenterologia y hepatologia. 33(4)
Patients with liver disease frequently experience changes in their nutritional status.To determine changes in vitamin B12 and folic acid plasma levels in patients with chronic cirrhosis and to assess whether these parameters may be useful in the etio
Publikováno v:
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 9(11)
1. Liver grafts from hepatitis C virus (HCV)-infected deceased donors can be used safely in HCV-infected recipients. 2. Histological assessment of the graft before orthotopic liver transplantation (OLT) is advised. 3. Recipients of these grafts shoul